drugset / Trial / NCT01261741

Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

NCT01261741

Phase 2 Completed 299 enrolled Merz Pharmaceuticals GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.

Timeline

Start
2010-11
Primary completion
2011-08
Completion
2011-09

Publications

  • Results Schulz JB, Acker C, Seitzinger A, Pulte I. Randomized, double-blind, placebo-controlled, multicentre study to investigate memantine in the treatment of memory, concentration, and attention problems (subjective cognitive impairment). Journal of the Neurological Sciences 333 Suppl.1: e332, 2013. doi:10.1016/j.jns.2013.07.1232

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg